Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...

Glox Therapeutics secures £500K from a £3M fund to develop antibiotics targeting antimicrobial-resistant lung infections in ...

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

"Glox to develop precision antibiotics for cystic fibrosis" was originally created and published by Pharmaceutical Technology ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

The star joined forces with Dermot Bannon to achieve his goal of opening a home away from home for the families of cystic ...

Some people with cystic fibrosis still do not have access to the life-changing modulator therapy drugs, despite wider EMA ...

K grant to accelerate development of Glox Therapeutics' novel precision antibiotics targeting AMR lung infections in people ...